| Literature DB >> 35516591 |
Fateme Nazary Abrbekoh1, Leila Salimi1, Sepideh Saghati1, Hassan Amini1, Sonia Fathi Karkan1, Keyvan Moharamzadeh2, Emel Sokullu3, Reza Rahbarghazi1,4.
Abstract
In the past decade, microneedle-based drug delivery systems showed promising approaches to become suitable and alternative for hypodermic injections and can control agent delivery without side effects compared to conventional approaches. Despite these advantages, the procedure of microfabrication is facing some difficulties. For instance, drug loading method, stability of drugs, and retention time are subjects of debate. Besides, the application of novel refining fabrication methods, types of materials, and instruments are other issues that need further attention. Herein, we tried to summarize recent achievements in controllable drug delivery systems (microneedle patches) in vitro and in vivo settings. In addition, we discussed the influence of delivered drugs on the cellular mechanism and immunization molecular signaling pathways through the intradermal delivery route. Understanding the putative efficiency of microneedle patches in human medicine can help us develop and design sophisticated therapeutic modalities.Entities:
Keywords: Microneedle patches; delivery system; diabetes; drugs; transdermal injection
Year: 2022 PMID: 35516591 PMCID: PMC9065468 DOI: 10.1177/20417314221085390
Source DB: PubMed Journal: J Tissue Eng ISSN: 2041-7314 Impact factor: 7.940
Figure 1.Available approached purposed for transdermal delivery using MN patch system.
Figure 2.(a) MN fabrication methods are a subset of micro-electro-mechanical fabrication processes that diverged into three major groups: bulk micromachining, surface micromachining, and LIGA. (b) Photolithography process is one of the methods to the pattern desired figures on biomaterials, subsequently creating the 3D shape via wet or dry etching.
Figure 3.Several micromolding-based MN fabrication techniques: (a) micromolding, (b) injection molding, (c) hot embossing, and (d) investment molding.
Figure 4.Types of MNs with different releasing mechanisms.
Figure 5.Smart MN types. The smart MN response to the environmental changes allowed controllable factor release. Smart MNs were divided into two major groups exogenous- and endogenous-based stimuli.
Figure 6.(a) Application of PVP/PVA-based MN containing polymeric vesicles consisted of PPBEM, as H2O2-sensitive material, (PEG)/PPBA, as glucose-sensitive material for transdermal delivery of insulin in a rat model of diabetes. Local accumulation of glucose activates glucose oxidase (GOx), leading to the production of H2O2 and gluconic acid. In the next step, the exposure of PPBEM to PPBEM supports the release of loaded insulin into the systemic circulation. (b) NIR emission elicits Prussian blue nanoparticles that transform light to heat. After heat production, the coated lauric acid was dissolved, causing metformin relinquishment.
Figure 7.Representative illustration related to fabrication and application of insulin-loaded powder-carrying microneedle using PDMS mold, and CMC solution (a). Dissolving MNs possess empty cavities. Upon detachment of MNs from the mold, insulin powder was loaded into the micro-cavities and coated with CMC film (b). The insertion of these MNs into the cutaneous layer leads to the breakage of the CMC layer at the base of patches. The retraction contributes to the remaining of MNs within the cutaneous layer (c). These MNs adsorb the interstitial fluid thus insulin is released accordingly.
Source: Adapted with permission; Copyright 2020; Biomaterials.
Different MN types and applications.
| Drug Name | MN type | Fabrication method | Material | Mechanism of action | Therapeutic applicants | Ref |
|---|---|---|---|---|---|---|
| Lysozyme enzyme | Dissolving MN | Micromolding | Polyvinylpyrrolidone, hyaluronic acid, and poly(lactic-co-glycolic acid) | Breaking glycosidic bond in peptidoglycans | Antibiotic for dermal use | Panda et al.
|
| Resveratrol | Dissolving MN | Micromolding | Eudragit/PVP-K90/Resveratrol | Inhibiting TGFβ/SMAD pathway | Cosmetic, skin cancer, cardiovascular disease | Aung et al.
|
| Nicotine | Dissolving MN | Micromolding | Polyvinylpyrrolidone/Nicotine | PI3K-Akt signaling pathway | Smoking addiction | Panda et al.
|
| Silver nanoparticle | Dissolving MN | Micromolding | Silver nanoparticles were encapsulated in Polycaprolactone/Chitosan as microparticles surrounded by Polyvinylpyrrolidone/Polyvinyl alcohol | Inhibition PI3K/AKT signaling pathway by ROS production, Interruption cell wall | Infectious chronic wound | Permana et al.
|
| Dexamethasone | Dissolving MN | Micromolding | Hyaluronic acid and Collagen were encapsulated inside poly(lactic-co-glycolic acid) and loaded with Dexamethasone | Inhibition of NLRP3 and IL-1β production | Inflammatory skin disorders | Wan et al.
|
| Rosi | Smart/Dissolving MN | Micromolding | Polyvinyl alcohol/Melanin/Rosi | Inhibition of peroxisome proliferator-activated receptor (PPAR) | Obesity | Peng et al.
|
| Capsaicin | Dissolving MN | Micromolding | Capsaicin was encapsulated in α-Lacnano micelles/Hyaluronic acid/Polyvinyl alcohol | Reduction of PPARγ, C/EBPα | Obesity | Bao et al.
|
| Lix | Dissolving MN | Micromolding | PVPk29/32/Lix | cAMP/PKA, PIP3/PKC, and PI3K/AKT signaling pathways | Diabetes | Zhu et al.
|
| Glucagon | Swellable MN | Micromolding | Methacrylated hyaluronic acid/Glucagon loaded in microgels consist of zwitterionic sulfobetaine (SB), 4-acrylamide-3-fluorophenylboronic acid (AFBA), and cationic carboxybetaine (CB) | cAMP/PKA and PIP3/PKC signaling pathways | Diabetes | GhavamiNejad et al.
|
| Viral subunit | Dissolving MN | Micromolding | PVP/Lyophilized monovalent subunit influenza vaccine (A/Brisbane/10/10 (H1N1)) | Biodegradation | Vaccination | Kim et al.
|
| mRNA | Dissolving MN | Micromolding | PVP/Naked luciferase mRNA | Biodegradation | Transfection | Koh et al.
|
| Viral vector loaded antigen-adjuvant | Dissolving MN | Micromolding | Carboxymethyl cellulose/trehalose loaded ovalbumin mRNA with Poly(I:C) (TLR3 against) | Biodegradation | Vaccination/Transfection | Erdos et al.
|
| Non-viral vector loaded DNA | Dissolving MN | Micromolding | PVA/PVP encapsulated poly lactic-co-glycolic acid—poly-lysine/poly-γ-glutamic acid (PLGA-PLL/γPGA) nanoparticles/Ebo DNA | Biodegradation | Transfection | Yang et al.
|
| Viral subunit coadjuvant | Dissolving MN | Micromolding | Sucrose/gelatin encapsulated P47/CpG oligonucleotide | Biodegradation | Transfection | Yenkoidiok-Douti et al.
|
| Viral subunit coadjuvant | Dissolving MN | Micromolding | PVA/sucrose loaded H1N1 co cGMP/saponin | Biodegradation | Transfection | Vassilieva et al.
|
| DNA encoded bacteria toxin | Dissolving MN | Micromolding | Hyaluronic acid loaded pVAX1 (plasmid DNA) encoded Ag85B of Mycobacterium tuberculosis | Biodegradation | Transfection | Yan et al.
|
| Non-viral vector loaded DNA | Dissolving MN | Micromolding | PVA loaded RALA/pPSCA (Prostate Stem Cell Antigen) | Biodegradation | Transfection | Cole et al.
|
Figure 8.Schematic of antigen-specific immunogenicity by MN delivery system. MN arrays can deliver antigen/or therapeutic agents into the dermal layers. In the next steps, antigens are processed by local APCs, leading to activation of T lymphocytes (CD8, CD4+ lymphocytes) and B cells. In addition to the production of numerous cytokines, immune cells like NK cells and CD8 lymphocytes can directly invade the tumor cells.
Some list of MN patch clinical trials recorded up to January 2022 (available at https://clinicaltrials.gov/us).
| Status | Object | Phase |
|---|---|---|
| Enrolling by invitation | Brightening cutaneous tissue using MN in individuals with solar Lentigines | Not Applicable |
| Completed | Local delivery of Lidocaine for oral anesthesia using MN | Phase I |
| Completed | Vaccination against viruses in healthy infants/young children using MN | Not Applicable |
| Completed | Diabetes diagnosis and glucose monitoring using MN | Not Applicable |
| Unknown | MN for the treatment of psoriatic plaques | Not Applicable |
| Suspended | Pilocarpine microneedles for sweat induction in cystic fibrosis patients using MN | Not Applicable |
| Completed | Vaccination against influenza | Phase I |
| Recruiting | Vaccination against measles and rubella | Phases I and II |
| Recruiting | Efficacy of transdermal microneedle patch for topical anesthesia enhancement in pediatric thalassemia patients | Phase II |
| Recruiting | MN for delivery of Doxorubicin in patients with cutaneous T-cell Lymphoma | Phase I |
| Completed | Dose-limiting toxicity and maximum tolerated dose of MN containing Doxorubicin in basal cell carcinoma | Phase I |
| Recruiting | Evaluation of cutaneous micropores after application of MN | Not Applicable |
| Completed | Physiological study to determine the allergic skin activity after different skin preparation using MN | Phase I |
| Completed | Pain and safety of microneedles in oral cavity | Not Applicable |
| Completed | Minimally invasive sensing of beta-lactam antibiotics | Phase I |
| Unknown | Microneedle and trichloroacetic acid in treatment of melasma | Not Applicable |
| Recruiting | Microneedles for diagnosis of latent tuberculosis | Not Applicable |
| Unknown | Microneedle radiofrequency for moderate-to-severe acne vulgaris | Not Applicable |
MN: microneedle patch.